EUVIMEDOdkrijte EUVIMED
CrossrefInformačná karta

The Role Of Renal Resistive Index (RRI) As Early Non Invasive Predictor Of Renal Dysfunction And Relation To Estimated GFR In NAFLD Patients

Atteyat Aboelmaged Semeya, Hala Abd-Elhameed Tabl, Naglaa F. AL-Mihy

Journal of Medicine in Scientific Research · 2024-01-01 · 7 (3)

DOI: 10.59299/2537-0928.1394 ↗
AbstraktBibliografické údaje

Abstrakt

Background: Non-alcoholic fatty liver (NAFLD) is the diagnosis of fatty infiltration of the liver (steatosis) in the absence of other reasons, done through histology or imaging, with or without fibrosis or inflammation. We sought to ascertain the function of RRI as early non-invasive predictor of renal dysfunction and the relationship between eGFR and RRI in patients with NAFLD. Methods: This cross-sectional research comprised 250 patients and controls gathered from outpatient clinic of the Hepatogasteroenterology Department, Benha teaching Hospitals. They were split into three groups: group 1 consisted of 100 NASH patients, fibrosis-free or with a history of the condition; group 2 comprised 100 patients with simple steatosis; and group 3 consisted of an additional 50 healthy, normal controls. All patients underwent laboratory investigations including tests for the lipid profile, liver function, kidney function, and fasting blood glucose (FBG) and radiological assessment using an abdominal U/S. Results: RRI and NAFLD fibrosis score were significantly greater in group one in contrast to groups two and three (P0.063, with 100% sensitivity, 60.67% specificity, 62.9% PPV and 100% NPV. Conclusions: We concluded that NAFLD are associated with higher RRI, NAFLD fibrosis score, FBG, serum creatinine, hazardous lipid profile and liver enzymes and lower eGFR.

Vedomosti, ktoré zodpovedajú vašej práci.

Od bezplatného začiatku cez osobnú rešerš literatúry až po kompletný Research Suite.

Zobraziť tarify →

Sú zahrnuté všetky plné texty vydavateľov?

Nie. Bibliografické záznamy, abstrakty a plné texty sú odlišné typy obsahu. To, či je plný text dostupný, závisí od zdroja, Open Access a vašich existujúcich licencií. Tarif EUVIMED nenahrádza dodatočné práva vydavateľa.

Zobraziť tarify →